“Now that we have identified SOX10 as an initiator of myelination, we can work on developing a viral or pharmaceutical approach to inducing it in MS patients,” says Fraser J. Sim, PhD, assistant professor and senior author of the paper.
Transcription factors are proteins or molecules that bind to DNA and alter which genes are turned on, or expressed.
“If we could create a drug that would switch on SOX10, that would be therapeutically important,” Sim explains.
Removing Barriers to MS Stem Cell Therapy
Targeting SOX10 offers hope for a viable stem cell treatment for MS.
Long seen as having dramatic potential for treating